The news: Digital health company Noom is rolling out a new preventive health program that offers microdoses of GLP-1 medications alongside at-home biomarker testing.

• Eligible patients are prescribed small, personalized doses of compounded GLP-1s.
• At-home test kits measure 17 lab markers spanning metabolic, cardiovascular, and hormonal health. The tests are separate from the GLP-1 microdoses, but packaged together in a program designed to help people take a more proactive approach to their health.
• Members also gain access to Noom’s digital behavioral coaching program.
• The program is $149 per month.

Why it matters: The program is designed for people with a BMI of 21 or higher, including many in the “healthy weight” range, as defined by the CDC (BMI of 18.5 to 24.9). Noom was previously offering microdoses of compounded GLP-1 semaglutide for weight loss for people with a BMI of 25 or higher. For context, GLP-1s are only FDA-approved for people whose BMI is at least 30, or for people with a BMI of 27 and who have a weight-related health condition.

Online healthcare companies are increasingly marketing GLP-1s to people who aren’t overweight or obese.

• More providers are prescribing GLP-1 microdoses off-label to patients who don’t meet standard BMI criteria, arguing it’s acceptable because the doses are only a fraction of the recommended starter amount.
• Telehealth players Hims & Hers, Found, and Midi Health offer compounded microdoses of GLP-1s.
• 36% of GLP-1 users report that they’re microdosing their medication, per an April 2025 Tebra survey.
• Reducing side effects, easing into the treatment gradually, and saving money are the top reasons GLP-1 users microdose.

Implications for telehealth companies: With brand-name GLP-1 prices dropping, telehealth players in the weight loss drug space need a new strategy to attract and retain members.

The GLP-1 microdosing wave gives telehealth companies an opportunity to access far more patients beyond those who are overweight and obese. Noom says that by lowering the BMI threshold to 21 and up, “the vast majority of US adults” could be eligible for its new program. At-home biomarker testing provides extra value for wellness enthusiasts by including tests that primary care doctors don’t typically order. With similar capabilities now offered by D2C healthcare companies like Hims, Noom, Ro, and WeightWatchers, differentiation will hinge on cost and accessible coaching/support—especially guidance through untested areas like microdosing weight loss drugs.